- /
- Supported exchanges
- / US
- / TECX.NASDAQ
Tectonic Therapeutic, Inc. (TECX NASDAQ) stock market data APIs
Tectonic Therapeutic, Inc. Financial Data Overview
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tectonic Therapeutic, Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Tectonic Therapeutic, Inc. data using free add-ons & libraries
Get Tectonic Therapeutic, Inc. Fundamental Data
Tectonic Therapeutic, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -82 661 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Tectonic Therapeutic, Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-02-27
- EPS/Forecast: -1.1143
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tectonic Therapeutic, Inc. News
New
TD Asset Management Inc. Announces TD ETF Distributions
TORONTO, March 19, 2026 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the March cash distributions for the TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") and ...
Tectonic Therapeutics' Q4 Net Loss Widens; Phase 2 APEX Trial Data Due In 2026
(RTTNews) - Tectonic Therapeutics, Inc. (TECX), a clinical-stage biotechnology company, reported fourth-quarter and full-year 2025 results and provided an update on the progress of its clinical pipeli...
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) ...
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery an...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.